Si-Bone (NSDQ:SIBN) last week closed an initial public offering that brought in much more than anticipated for its iFuse sacroiliac implant. The Santa Clara, Calif.-based company priced the 7.2-million-share flotation at $15 per share, which at $108 million would have topped its initial range of about $90 million to nearly $104 million (which itself would have beaten […]
Funding Roundup
New eye health companies gain funders’ focus
Startups pioneering less-invasive technologies to treat common eye diseases are changing the outlook for both patients and the industry. A new study by CB Insights revealed that investors have been pouring money into smaller companies in 2017 and 2018, with some FDA approvals to begin marketing their technologies and treatments. These firms are eyeing conditions […]
Si-Bone prices upsized $108m IPO
Si-Bone yesterday priced its initial public offering, which launched today, lifting the total it hopes to bring in from a previous maximum of $103.5 million up to $108 million. In the offering, the Santa Clara, Calif.-based company said it will offer 7.2 million shares at $15 per share. Si-Bone had previously said it expected to offer […]
Nanobiotix reels in $18.5m tranche from European Investment Bank
Nanobiotix (PAR:NANO.PA) received €16 million ($18.5 million) in the first tranche of a previously-announced non-dilutive loan from the European Investment Bank. The five-year funding deal is designed to support the company’s development of nanoparticle-based cancer therapies. Get the full story at our sister site, Drug Delivery Business News.
Valeritas aims for $50m in stock offering
Valeritas (NSDQ:VLRX) said this week that it plans to offer 37,593,984 shares of its common stock, hoping to raise $50 million in gross proceeds. The medical technology company also announced its preliminary financial results this week for the third quarter of 2018. Get the full story at our sister site, Drug Delivery Business News.
ReWalk Robotics dips on Q3 prelims, registers $15m offering
ReWalk Robotics (NSDQ:RWLK) shares took a hit today after the rehabilitation exoskeleton maker posted preliminary third-quarter sales that missed the mark on Wall Street, even as the company revealed plans for a $15 million public offering. The Yokneam, Israel-based company also registered a $14.8 million offering of stock and other securities. ReWalk said it expects […]
Vascular Therapies raises $12m for drug-eluting vascular access implant
Vascular Therapies has raised $12.4 million from 29 investors as part of a $21.1 million round, according to a document filed last week with the SEC. The Cresskill, N.J.-based company is developing a sirolimus-eluting collagen implant for patients with end-stage renal disease. The bioresorbable drug-delivery system is designed to keep open a portal of entry […]
Rgenix raises $40M to develop novel cancer drugs
Biopharma startup Rgenix said it has raised $40 million in Series C financing to further develop its clinical and pre-clinical oncology programs and for general corporate purposes. New York City-based Rgenix has discovered several novel RNA-regulated cancer targets that drive tumor growth and cancer progression, according to its website. These targets regulate key components of the tumor […]
Glympse Bio raises $22M for disease-detecting sensors
Sensor-driven disease detection company Glympse Bio has raised $22 million in a Series A round to fund clinical trials for its technology. The Cambridge, Mass.-based company uses bioengineered activity sensors transported to the site of disease in patients to investigate biological targets such as proteases – a class of enzymes that drive critical disease pathways. Once a disease […]
Cardialen raises $17m Series B
Cardialen said today that it closed a $17 million Series B round for the low-energy defibrillation technology it’s developing. The Minneapolis-based company said RiverVest Venture partners led the round, joined by Qiming Venture Partners, HBM Healthcare Investments and Cultivation Capital. The proceeds are earmarked for further clinical work on Cardialen’s “unpinning termination” therapy, which is designed to […]
Report: Medical device deal volume, spend down during Q3
Investors spent less money on fewer deals in the medical device sector during the third quarter and so far this year, bucking the overall growth trend for venture capital-backed firms, according to a new report. Venture capital investment fell -19.7% to $772.7 million during the three months ended Sept. 30, with deal volume down -20.3% […]